Junbin Qian
Overview
Explore the profile of Junbin Qian including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
30
Citations
2056
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ai C, Li H, Wang C, Ji Y, Wallace D, Qian J, et al.
JCI Insight
. 2025 Mar;
PMID: 40036074
Leber hereditary optic neuropathy (LHON) is a paradigm for mitochondrial retinopathy due to mitochondrial DNA (mtDNA) mutations. However, the mechanism underlying retinal cell-specific effects of LHON-linked mtDNA mutations remains poorly...
2.
Wang H, Chen J, Chen X, Liu Y, Wang J, Meng Q, et al.
Cancer Res
. 2024 Sep;
84(20):3371-3387.
PMID: 39250301
Tumor stroma plays a critical role in fostering tumor progression and metastasis. Cancer-associated fibroblasts (CAF) are a major component of the tumor stroma. Identifying the key molecular determinants for the...
3.
Li Y, Yang Y, Xue Y, Lei H, Zhang S, Qian J, et al.
Elife
. 2024 Jun;
12.
PMID: 38836551
Tuft cells are a group of rare epithelial cells that can detect pathogenic microbes and parasites. Many of these cells express signaling proteins initially found in taste buds. It is,...
4.
Franken A, Bila M, Mechels A, Kint S, Van Dessel J, Pomella V, et al.
Immunity
. 2024 Mar;
57(3):541-558.e7.
PMID: 38442708
Cancer patients often receive a combination of antibodies targeting programmed death-ligand 1 (PD-L1) and cytotoxic T lymphocyte antigen-4 (CTLA4). We conducted a window-of-opportunity study in head and neck squamous cell...
5.
Cappuyns S, Philips G, Vandecaveye V, Boeckx B, Schepers R, Van Brussel T, et al.
Nat Commun
. 2023 Nov;
14(1):7825.
PMID: 38030622
The combination of atezolizumab plus bevacizumab (atezo/bev) has dramatically changed the treatment landscape of advanced HCC (aHCC), achieving durable responses in some patients. Using single-cell transcriptomics, we characterize the intra-tumoural...
6.
Sang W, Zhou Y, Chen H, Yu C, Dai L, Liu Z, et al.
Cancer Discov
. 2023 Oct;
14(2):326-347.
PMID: 37824278
Significance: PDAC is resistant to almost all available therapies, including immune checkpoint blockade. Through in vivo CRISPR screen, we identified that RIPK2 plays a crucial role in facilitating immune evasion...
7.
Chen S, Cui W, Chi Z, Xiao Q, Hu T, Ye Q, et al.
Cell Metab
. 2022 Sep;
34(11):1843-1859.e11.
PMID: 36103895
The tumor microenvironment (TME) is a unique niche governed by constant crosstalk within and across all intratumoral cellular compartments. In particular, intratumoral high potassium (K) has shown immune-suppressive potency on...
8.
Wu Z, Wang M, Liang G, Jin P, Wang P, Xu Y, et al.
Front Immunol
. 2021 Dec;
12:772729.
PMID: 34956198
Recurrent pregnancy loss (RPL), especially the unexplained RPL, is associated with the disruption of maternal immune tolerance. However, little is known about the immune status at the decidua of RPL...
9.
Llorens-Rico V, Gregory A, Van Weyenbergh J, Jansen S, Van Buyten T, Qian J, et al.
Nat Commun
. 2021 Oct;
12(1):6243.
PMID: 34716338
Understanding the pathology of COVID-19 is a global research priority. Early evidence suggests that the respiratory microbiome may be playing a role in disease progression, yet current studies report contradictory...
10.
Feng M, Wu Z, Zhou Y, Wei Z, Tian E, Mei S, et al.
Signal Transduct Target Ther
. 2021 Aug;
6(1):313.
PMID: 34417435
To date, the overall response rate of PD-1 blockade remains unsatisfactory, partially due to limited understanding of tumor immune microenvironment (TIME). B-cell lymphoma 9 (BCL9), a key transcription co-activator of...